CD34 and angina pectoris: Another more recent clinical trial further identified previous smoking habit, female gender, lower grades of angina score, and diastolic dysfunction as independent promising predictors of CD34+ cell therapy in patients diagnosed with end-stage diffuse coronary artery disease [45].